Vanguard Research Group, a Manhasset company owned by North Shore-Long Island Jewish Health System and one of its executives, has signed a four-year, $28.8 million agreement to manage a clinical trial for an injectable form of a schizophrenia drug.
Phone: 718-470-8094
Vanguard Research Group, a Manhasset company owned by North Shore-Long Island Jewish Health System and one of its executives, has signed a four-year, $28.8 million agreement to manage a clinical trial for an injectable form of a schizophrenia drug.